Andreas Kaubisch

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.

Charles Hesdorffer, Janet Ayello, Maureen Ward et al. · Journal of Clinical Oncology · 1998 · 218 citations

Medicine, Oncology, Pharmacology +16

Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice

Hongwei Wang, Madhukumar Venkatesh, Hao Li et al. · Journal of Clinical Investigation · 2011 · 142 citations · Full text

Medicine, Oncology, Pharmacology +17

Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo.

J A Titus, Pilar Pérez, Andreas Kaubisch et al. · The Journal of Immunology · 1987 · 133 citations

Life Sciences, Immunology, Oncology +17

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

Markus Moehler, Jeong Heo, H.C. Lee et al. · OncoImmunology · 2019 · 130 citations · Full text

Medicine, Immunology, Oncology +17